Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

PARIS, March 6, 2025 /PRNewswire/ -- Havas Health Network is launching its groundbreaking GLP-1 consultancy in Europe with flagship event, "Shape Shifting: A Close Look at the Health and Wellness ...

John Etnyre receives funding from the National Science Foundation and the Elaine M. Hubbard Distinguished Faculty Award When you look at your surrounding environment, it might seem like you’re ...

As plans to rebuild Interstate 375 in Detroit move forward, historians and residents are seeking to preserve the history of neighborhoods known as Black Bottom and Paradise Valley, whose ...

Canada Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with ...

The result? A self-healing, shape-shifting system that could change how we build and interact with materials. “We’ve figured out a way for robots to behave more like a material,” said Matthew Devlin, ...

STAYING IN SHAPE is a continuous process. If you've ever had to press pause on your routine, changed up your lifestyle, moved away from your favorite gym, or just fallen out of the habit of ...

We have a rough idea of the size and shape of this field, but the fine particulars elude our understanding. Now, a new computational study has revealed a surprising structure – a spiral generated by ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...